Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 TxCell Gains GMP Certificate for Cell Therapy Mfg. Facility | Contract Pharma

What are you searching for?

Sign in
Breaking News

TxCell Gains GMP Certificate for Cell Therapy Mfg. Facility

Will manufacture Phase IIb batches of Ovasave for Crohn’s trial

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

TxCell SA has received a certificate of GMP compliance by the French National Agency for Drug Safety (ANSM) for its cell therapy manufacturing facility in Besançon, France. The GMP compliance covers the manufacture, testing, blinding activities and release of investigational biologics and cell therapy products. It also authorizes the manufacture of Phase IIb clinical batches of Ovasave, a personalized cell-based immunotherapy for refractory Crohn’s disease, which is scheduled to start in 1H14.
 
“This certificate of Good Manufacturing Practices compliance is a result of the outstanding work of the TxCell’s teams. We have now achieved another of our strategic objectives to be able to offer a new therapeutic option for patients without effective treatment,” said Eric Pottier, vice president of Supply Chain & Qualified Person, TxCell.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics